Results of the PI3K delta study developed by Celon Pharma – CPL302-253 – have been published in the prestigious PLOS Magazine Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma presents the results of the development of a preclinical, highly specific and safe PI3K delta inhibitor – inhalation drug candidate in asthma and COPD.
The authors concluded that the molecule has not only therapeutic, but also preventive potential – due to its proven safety in asthma treatment. It is currently the only PI3K delta inhibitor developed in the form of an inhalant used in asthma and COPD therapy. PLOs is one of the most recognised open access journals, which publishes the results of basic and preclinical studies. Its articles are reviewed by over 3,000 scientists from around the world.